Skip to main content
main-content

14.11.2017 | Review

Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis

Zeitschrift:
Neurosurgical Review
Autoren:
Davide Tiziano Di Carlo, Federico Cagnazzo, Nicola Benedetto, Riccardo Morganti, Paolo Perrini
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s10143-017-0928-7) contains supplementary material, which is available to authorized users.

Abstract

Multiple high-grade gliomas (M-HGGs) are well--separated tumors, differentiated as multifocal (MF) and multicentric (MC) by their MRI features. The authors performed a systematic review and meta-analysis of literature examining epidemiology, clinical and radiological characteristics, management, and the overall survival from M-HGGs. According to PRISMA guidelines, a comprehensive review of studies published between January 1990 and January 2017 was carried out. The authors identified studies that examined the prevalence rate, clinical and radiological characteristics, treatment, and overall survival from M-HGGs in patients with HGG. Data were analyzed using a random-effects meta-analysis model. Finally, we systematically reviewed demographic characteristics, lesion location, and surgical and adjuvant treatments. Twenty-three studies were included in this systematic review. The M-HGGs prevalence rate was 19% (95% CI 13–26%) and the hazard ratio of death from M-HGGs in the HGGs population was 1.71 (95% CI 1.49–1.95, p < 0.0001). The MC prevalence rate was 6% (CI 95% 4–10%), whereas MF prevalence rate was 11% (CI 95% 6–20%) (p < 0.0001). There were no statistically significant differences between MF and MC HGGs in gender, lesion location, histological type, and surgical treatment. Survival analysis of MC tumors showed that surgical resection (gross total resection or subtotal resection) is an independent predictor of improved outcome (HR 7.61 for biopsy subgroup, 95% CI 1.94–29.78, p = 0.004). The prevalence of M-HGGs is approximately 20% of HGGs. The clinical relevance of separating M-HGGs in MF and MC tumors remains questionable and its prognostic significance is unclear. When patient status and lesion characteristics make it safe and feasible, cytoreduction should be attempted in patients with M-HGGs because it improves overall survival.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Online Resource 1 Literature search syntax (PDF 100 kb)
10143_2017_928_MOESM1_ESM.pdf
Online Resource 2 Discrepancies between authors in systematic review process (PDF 342 kb)
10143_2017_928_MOESM2_ESM.pdf
Online Resource 3 Discrepancies between authors in quality score assignment (PDF 328 kb)
10143_2017_928_MOESM3_ESM.pdf
Online Resource 4 Supplementary Figs. 1 and 2 Forest plot of overall MF and MC tumors prevalence in HGGs population. Supplementary Figs. 3 and 4 Meta-regression and funnel plot from survival meta-analysis (PDF 583 kb)
Online Resource 5 Multifocal versus multicentric tumors: demographics data and lesion location (PDF 114 kb)
10143_2017_928_MOESM5_ESM.pdf
Online Resource 6 Comparison of surgical treatment rates in M-HGGs population (PDF 331 kb)
10143_2017_928_MOESM6_ESM.pdf
Online Resource 7 Surgical and adjuvant treatments of multifocal and multicentric HGGs (PDF 109 kb)
10143_2017_928_MOESM7_ESM.pdf
Literatur
Über diesen Artikel
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise